Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 22

1.

Bone Age and Mineral Density Assessments Using Plain Roentgenograms in Tenofovir-exposed Infants in Malawi and Brazil Enrolled in HIV Prevention Trials Network 057.

Osorio LE, Boechat MI, Mirochnick M, Kumwenda N, Kreitchmann R, Emel L, Pinto J, Joao E, Santos B, Swenson M, George K, Sato P, Mofenson L, Nielsen-Saines K; HIV Prevention Trials Network (HPTN) 057 Protocol Team..

Pediatr Infect Dis J. 2017 Feb;36(2):184-188. doi: 10.1097/INF.0000000000001386.

2.

Disclosing in utero HIV/ARV exposure to the HIV-exposed uninfected adolescent: is it necessary?

Jao J, Hazra R, Mellins CA, Remien RH, Abrams EJ.

J Int AIDS Soc. 2016 Oct 13;19(1):21099. doi: 10.7448/IAS.19.1.21099. eCollection 2016.

3.

In Utero Tenofovir Exposure Is not Associated With Fetal Long Bone Growth.

Jao J, Abrams EJ, Phillips T, Petro G, Zerbe A, Myer L.

Clin Infect Dis. 2016 Jun 15;62(12):1604-9. doi: 10.1093/cid/ciw159. Epub 2016 Mar 23.

PMID:
27009251
4.

Meconium Tenofovir Concentrations and Growth and Bone Outcomes in Prenatally Tenofovir Exposed HIV-Uninfected Children.

Himes SK, Wu JW, Jacobson DL, Tassiopoulos K, Hazra R, Kacanek D, Van Dyke RB, Rich KC, Siberry GK, Huestis MA; Pediatric HIVAIDS Cohort Study (PHACS)..

Pediatr Infect Dis J. 2015 Aug;34(8):851-7. doi: 10.1097/INF.0000000000000747.

5.

Effects of anesthesia with isoflurane, ketamine, or propofol on physiologic parameters in neonatal rhesus macaques (Macaca mulatta).

Martin LD, Dissen GA, McPike MJ, Brambrink AM.

J Am Assoc Lab Anim Sci. 2014 May;53(3):290-300.

6.

Metabolic complications of in utero maternal HIV and antiretroviral exposure in HIV-exposed infants.

Jao J, Abrams EJ.

Pediatr Infect Dis J. 2014 Jul;33(7):734-40. doi: 10.1097/INF.0000000000000224. Review.

7.

Infant growth outcomes after maternal tenofovir disoproxil fumarate use during pregnancy.

Ransom CE, Huo Y, Patel K, Scott GB, Watts HD, Williams P, Siberry GK, Livingston EG; P1025 Team of the International Maternal Pediatric Adolescent AIDS Clinical Trials Group..

J Acquir Immune Defic Syndr. 2013 Dec 1;64(4):374-81. doi: 10.1097/QAI.0b013e3182a7adb2.

8.

Characteristics of foot fractures in HIV-infected patients previously treated with tenofovir versus non-tenofovir-containing highly active antiretroviral therapy.

Horizon AA, Joseph RJ, Liao Q, Ross ST, Pakes GE.

HIV AIDS (Auckl). 2011;3:53-9. doi: 10.2147/HIV.S15588. Epub 2011 Jun 28.

9.

In utero and postnatal exposure to antiretrovirals among HIV-exposed but uninfected children in the United States.

Griner R, Williams PL, Read JS, Seage GR 3rd, Crain M, Yogev R, Hazra R, Rich K; Pediatric HIV/AIDS Cohort Study..

AIDS Patient Care STDS. 2011 Jul;25(7):385-94. doi: 10.1089/apc.2011.0068. Epub 2011 Jun 10.

10.

Pharmacokinetics and placental transfer of single-dose tenofovir 1% vaginal gel in term pregnancy.

Beigi R, Noguchi L, Parsons T, Macio I, Kunjara Na Ayudhya RP, Chen J, Hendrix CW, M√Ęsse B, Valentine M, Piper J, Watts DH.

J Infect Dis. 2011 Nov 15;204(10):1527-31. doi: 10.1093/infdis/jir562. Epub 2011 Sep 19.

11.

Pharmacokinetics and safety of single-dose tenofovir disoproxil fumarate and emtricitabine in HIV-1-infected pregnant women and their infants.

Flynn PM, Mirochnick M, Shapiro DE, Bardeguez A, Rodman J, Robbins B, Huang S, Fiscus SA, Van Rompay KK, Rooney JF, Kearney B, Mofenson LM, Watts DH, Jean-Philippe P, Heckman B, Thorpe E Jr, Cotter A, Purswani M; PACTG 394 Study Team..

Antimicrob Agents Chemother. 2011 Dec;55(12):5914-22. doi: 10.1128/AAC.00544-11. Epub 2011 Sep 6.

12.

Safety and tolerability of antiretrovirals during pregnancy.

Weinberg A, Forster-Harwood J, Davies J, McFarland EJ, Pappas J, Kinzie K, Barr E, Paul S, Salbenblatt C, Soda E, Vazquez A, Levin MJ.

Infect Dis Obstet Gynecol. 2011;2011:867674. doi: 10.1155/2011/867674. Epub 2011 Apr 11.

13.

Clinical monitoring and correlates of nephropathy in SIV-infected macaques during high-dose antiretroviral therapy.

Sanders-Beer BE, Spano YY, Golighty D, Lara A, Hebblewaite D, Nieves-Duran L, Rhodes L, Mansfield KG.

AIDS Res Ther. 2011 Jan 21;8(1):3. doi: 10.1186/1742-6405-8-3.

14.

Aging, human immunodeficiency virus, and bone health.

Mansky KC.

Clin Interv Aging. 2010 Sep 23;5:285-92.

15.

Deep-coverage rhesus red blood cell proteome: a first comparison with the human and mouse red blood cell.

Pasini EM, Kirkegaard M, Mortensen P, Mann M, Thomas AW.

Blood Transfus. 2010 Jun;8 Suppl 3:s126-39. doi: 10.2450/2010.020S.

16.

Tenofovir treatment of primary osteoblasts alters gene expression profiles: implications for bone mineral density loss.

Grigsby IF, Pham L, Mansky LM, Gopalakrishnan R, Carlson AE, Mansky KC.

Biochem Biophys Res Commun. 2010 Mar 26;394(1):48-53. doi: 10.1016/j.bbrc.2010.02.080. Epub 2010 Feb 18.

17.

Tenofovir-associated bone density loss.

Grigsby IF, Pham L, Mansky LM, Gopalakrishnan R, Mansky KC.

Ther Clin Risk Manag. 2010 Feb 2;6:41-7.

18.

German-Austrian recommendations for HIV1-therapy in pregnancy and in HIV1-exposed newborn, update 2008.

Buchholz B, Beichert M, Marcus U, Grubert T, Gingelmaier A, Haberl A, Schmied B; German AIDS Society.; Austrian AIDS Society.; HIV-AIDS Competence Network.; Robert-Koch Institute Berlin.; German Association of Physicians Specialized in HIV Care.; German Society of Pediatric and Youth Medicine.; German AIDS Pediatric Association.; German Society of Obstetrics and Gynecology.; National Reference Center for Retroviruses.; German AIDS Assistance..

Eur J Med Res. 2009 Nov 3;14(11):461-79.

19.

Chronic administration of tenofovir to rhesus macaques from infancy through adulthood and pregnancy: summary of pharmacokinetics and biological and virological effects.

Van Rompay KK, Durand-Gasselin L, Brignolo LL, Ray AS, Abel K, Cihlar T, Spinner A, Jerome C, Moore J, Kearney BP, Marthas ML, Reiser H, Bischofberger N.

Antimicrob Agents Chemother. 2008 Sep;52(9):3144-60. doi: 10.1128/AAC.00350-08. Epub 2008 Jun 23.

20.

Tenofovir treatment augments anti-viral immunity against drug-resistant SIV challenge in chronically infected rhesus macaques.

Metzner KJ, Binley JM, Gettie A, Marx P, Nixon DF, Connor RI.

Retrovirology. 2006 Dec 21;3:97.

Supplemental Content

Support Center